Sign in

    Xiaotong Jia

    Research Analyst at Jefferies

    Xiaotong Jia is an equity research analyst at Jefferies LLC, specializing in coverage of the technology sector with a focus on software and internet companies. She is known for her analytical coverage of firms such as Microsoft, Salesforce, and ServiceNow, and her investment calls have generated solid track records as observable on financial data platforms, although specific ranking and return metrics are not publicly disclosed. Xiaotong Jia began her finance career in the late 2010s, joining Jefferies after roles with other financial institutions, and is currently registered with FINRA, holding the Series 7 and Series 63 securities licenses. Her research reputation is bolstered by her professional credentials and ongoing contributions to the equity research field.

    Xiaotong Jia's questions to Altimmune (ALT) leadership

    Xiaotong Jia's questions to Altimmune (ALT) leadership • Q3 2024

    Question

    Fiona, on behalf of Roger Song from Jefferies, asked whether the three additional indications for pemvidutide would be developed independently or as part of partnership discussions, and if the company's current cash runway extends to cover these new programs.

    Answer

    CEO Dr. Vipin Garg clarified that the new indications provide strategic optionality; Altimmune can develop them independently but they also enhance the value proposition for potential partners. He confirmed that the current cash runway, projected into H1 2026, is sufficient to fund the initial IND filings and Phase II proof-of-concept trials for these indications.

    Ask Fintool Equity Research AI